Summit Therapeutics Inc. financials
Key figures from Summit Therapeutics Inc.'s filings with the U.S. Securities and Exchange Commission: the latest quarter against a year earlier, and the trend across recent quarters and fiscal years.
Latest quarter vs a year earlier
| Metric | Sep 2024 | Sep 2023 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | — |
| Net income | -$56M | -$21M | -164.5% |
| Free cash flow | -$30M | -$15M | -103.0% |
| Gross margin | — | — | — |
| Operating margin | — | — | — |
| Net margin | — | — | — |
Quarterly trend
Fiscal years
| Fiscal year | Revenue | Net income | Net margin | Free cash flow | EPS (diluted) |
|---|---|---|---|---|---|
| FY Dec 2024 | $0 | -$221M | — | -$142M | -$0.31 |
| FY Dec 2023 | $0 | -$615M | — | -$77M | -$0.99 |
| FY Dec 2022 | $705,000 | -$79M | -11174.8% | -$42M | -$0.41 |
| FY Dec 2021 | $2M | -$89M | -4897.8% | -$73M | -$0.67 |
| FY Dec 2020 | $860,000 | -$53M | -6127.6% | -$49M | -$0.76 |
* Fiscal fourth quarter computed from the annual filing minus the three reported quarters. All figures from company filings with the SEC.